Investigational Drug Information for PF-04965842
✉ Email this page to a colleague
What is the drug development status for PF-04965842?
PF-04965842 is an investigational drug.
There have been 25 clinical trials for PF-04965842.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 8th 2018.
The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are six US patents protecting this investigational drug and one hundred and forty-nine international patents.
Summary for PF-04965842
| US Patents | 6 |
| International Patents | 149 |
| US Patent Applications | 38 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2018-03-08) |
| Vendors | 40 |
Recent Clinical Trials for PF-04965842
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis | Pfizer | Phase 2 |
| Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants | Pfizer | Phase 1 |
| Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation | Pfizer | Phase 1 |
Clinical Trial Summary for PF-04965842
Top disease conditions for PF-04965842
Top clinical trial sponsors for PF-04965842
US Patents for PF-04965842
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-04965842 | ⤷ Sign Up | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| PF-04965842 | ⤷ Sign Up | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| PF-04965842 | ⤷ Sign Up | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-04965842 | ⤷ Sign Up | Pyrrolo[2,3-D]pyrimidine derivatives | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-04965842 | ⤷ Sign Up | Pyrrolo[2,3-D]pyrimidine derivatives | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-04965842 | ⤷ Sign Up | Pyrrolo[2,3-D]pyrimidine derivatives | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-04965842
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-04965842 | Argentina | AR109688 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | Australia | AU2017332867 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | Brazil | BR112019005578 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | Canada | CA3033249 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | Chile | CL2019000727 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | China | CN109715608 | 2036-09-23 | ⤷ Sign Up |
| PF-04965842 | Colombia | CO2019002616 | 2036-09-23 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
